TD Private Client Wealth LLC Has $5.95 Million Stock Position in Pfizer Inc. $PFE

TD Private Client Wealth LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 52.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 233,680 shares of the biopharmaceutical company’s stock after purchasing an additional 80,571 shares during the quarter. TD Private Client Wealth LLC’s holdings in Pfizer were worth $5,954,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Capital Advisory Group Advisory Services LLC increased its stake in shares of Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 388 shares in the last quarter. Citizens National Bank Trust Department grew its holdings in Pfizer by 0.9% in the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after purchasing an additional 395 shares during the period. Peak Asset Management LLC increased its stake in Pfizer by 1.4% in the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after purchasing an additional 402 shares in the last quarter. Able Wealth Management LLC increased its stake in Pfizer by 2.0% in the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 413 shares in the last quarter. Finally, Boltwood Capital Management raised its holdings in shares of Pfizer by 0.7% during the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock valued at $1,485,000 after purchasing an additional 420 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PFE has been the subject of several research reports. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. HSBC restated a “buy” rating and set a $29.00 price objective on shares of Pfizer in a report on Wednesday, December 10th. Morgan Stanley cut their target price on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $27.88.

Pfizer Trading Down 0.8%

NYSE PFE opened at $25.28 on Tuesday. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The business has a fifty day simple moving average of $25.28 and a 200 day simple moving average of $24.97. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The firm has a market capitalization of $143.71 billion, a P/E ratio of 14.69 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla said Pfizer is positioning for a large consumer obesity market comparable to the post‑Viagra era, signaling management expects major commercial upside if obesity drugs reach broad consumer adoption. Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
• Positive Sentiment: Pfizer completed a roughly $10B Metsera (MTSR) acquisition and plans an expanded push into obesity drug development in 2026 — a strategic move that could accelerate participation in a high‑growth market. Pfizer CEO eyes big push towards obesity drug development in 2026 after $10B Metsera acquisition
• Positive Sentiment: New oncology data look encouraging: a Pfizer cancer combo showed stronger tumor shrinkage than standard therapy in advanced colorectal cancer, and Pfizer is advancing lung cancer and colorectal combo trials — positive clinical readthroughs that could support future oncology revenue. Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial Pfizer Advances New Lung Cancer Combo in Global Phase 2/3 Trial: What Investors Should Watch
• Positive Sentiment: Positive new data reported on the Braftovi regimen add to oncology momentum and validate parts of Pfizer’s targeted therapy franchise. Positive new data on Pfizer’s Braftovi regimen
• Neutral Sentiment: UBS commented favorably on the MTSR obesity deal’s strategic logic but kept a Neutral rating and a $25 price target, citing revenue uncertainty tied to several major drugs. UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE
• Neutral Sentiment: Brokerages’ consensus remains cautious — an average “Hold” rating was reported, reflecting mixed analyst views as investors weigh upside from obesity and oncology against near‑term revenue headwinds. Pfizer Inc. (NYSE:PFE) Receives Average Rating of “Hold” from Brokerages
• Neutral Sentiment: Management’s JPMorgan conference presentation (transcript) provides detail on strategy and pipeline but didn’t supply immediate financial surprises — useful for longer‑term modeling rather than a near‑term catalyst. Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Broader healthcare thematic coverage (ETF commentary) highlights GLP‑1 adoption and sector valuation dynamics that may benefit Pfizer indirectly but do not single out company‑level catalysts. This ETF Is Proof That the Healthcare Rebound Is Real (PFE)
• Negative Sentiment: An analysis flagged Pfizer’s near‑term risks: a looming patent cliff, rising debt from recent deals, and uneven revenue visibility — factors that support analyst caution and could pressure valuation if guidance or sales miss expectations. Pfizer’s Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.